ArticleTranslational cancer research2026
CLCA1 as an immune prognostic biomarker and therapeutic target in colorectal cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) progression is profoundly shaped by the tumor immune microenvironment. Increasing evidence suggests that dysregulated immune activation and immune evasion jointly contribute to tumor progression and therapeutic resistance. This study aims to identify novel immune-related biomarkers and explore combinatorial therapeutic strategies for overcoming immunosuppression in CRC by investigating the interplay between chloride channel accessory 1 (CLCA1)-mediated immune activation and serine proteinase inhibitor B9 (SERPINB9)-driven immune escape. Methods: Integrated multi-omics analyses were performed to identify key immune-related prognostic biomarkers in CRC and to construct a prognostic immune signature. The predictive performance of the model was validated in independent cohorts. Functional assays were conducted in female C57BL/6J mice to evaluate the effects of CLCA1 on tumor growth and immune cell infiltration. Mechanistic analyses were used to investigate the regulatory relationship between CLCA1 and SERPINB9. In addition, computational drug screening, together with structural and biophysical assays, was applied to identify candidate small molecules targeting CLCA1. Results: CLCA1 was identified as a central immune-related prognostic biomarker in CRC. A 14-gene immune signature effectively stratified patients into distinct risk groups and showed robust predictive value across independent cohorts. Functional studies demonstrated that CLCA1 overexpression suppressed tumor growth and promoted the infiltration of cytotoxic immune cells. Mechanistically, CLCA1 downregulated SERPINB9, a granzyme B (GZMB) inhibitor that plays a pivotal role in immune evasion. Notably, combined CLCA1/SERPINB9 expression status provided improved prognostic stratification compared with either marker alone. Computational screening further identified phloretin as a potential CLCA1-targeting compound, which was supported by structural and biophysical validation. Conclusions: These findings identify CLCA1 as a prognostic immune modulator and a potential therapeutic target in CRC. The functional interaction between CLCA1 and SERPINB9 highlights a mechanistic axis linking immune activation and immune escape. Moreover, phloretin emerges as a candidate small molecule for modulating CLCA1, although its
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.